Zoetis Inc (ZTS) Stake Lessened by Ffcm LLC
Ffcm LLC lowered its stake in shares of Zoetis Inc (NYSE:ZTS) by 7.1% during the 3rd quarter, HoldingsChannel reports. The fund owned 28,562 shares of the company’s stock after selling 2,199 shares during the quarter. Ffcm LLC’s holdings in Zoetis were worth $2,615,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently bought and sold shares of ZTS. BlackRock Inc. increased its holdings in Zoetis by 1.4% in the 3rd quarter. BlackRock Inc. now owns 37,653,394 shares of the company’s stock worth $3,447,546,000 after buying an additional 522,533 shares during the period. Polen Capital Management LLC increased its holdings in Zoetis by 3.9% in the 2nd quarter. Polen Capital Management LLC now owns 9,295,080 shares of the company’s stock worth $791,848,000 after buying an additional 351,447 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in Zoetis by 1.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 7,692,247 shares of the company’s stock worth $704,302,000 after buying an additional 119,154 shares during the period. Wells Fargo & Company MN increased its holdings in Zoetis by 9.1% in the 2nd quarter. Wells Fargo & Company MN now owns 6,375,146 shares of the company’s stock worth $543,099,000 after buying an additional 529,666 shares during the period. Finally, Janus Henderson Group PLC increased its holdings in Zoetis by 22.3% in the 2nd quarter. Janus Henderson Group PLC now owns 5,410,040 shares of the company’s stock worth $460,890,000 after buying an additional 985,586 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.
In other news, CEO Juan Ramon Alaix sold 150,306 shares of the stock in a transaction that occurred on Thursday, November 8th. The stock was sold at an average price of $94.96, for a total transaction of $14,273,057.76. Following the transaction, the chief executive officer now owns 246,319 shares in the company, valued at approximately $23,390,452.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Roxanne Lagano sold 2,000 shares of the stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $92.03, for a total value of $184,060.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 163,806 shares of company stock worth $15,547,088. Insiders own 0.35% of the company’s stock.
Zoetis stock opened at $88.68 on Thursday. The company has a debt-to-equity ratio of 3.04, a quick ratio of 2.63 and a current ratio of 4.06. Zoetis Inc has a 12 month low of $70.20 and a 12 month high of $96.57. The company has a market capitalization of $43.29 billion, a price-to-earnings ratio of 36.95, a P/E/G ratio of 1.78 and a beta of 0.97.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, November 1st. The company reported $0.83 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.06. Zoetis had a return on equity of 75.51% and a net margin of 20.35%. The business had revenue of $1.48 billion for the quarter, compared to analyst estimates of $1.46 billion. During the same quarter in the prior year, the firm posted $0.65 EPS. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. Sell-side analysts expect that Zoetis Inc will post 3.11 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Tuesday, November 20th will be given a $0.126 dividend. The ex-dividend date is Monday, November 19th. This represents a $0.50 annualized dividend and a yield of 0.57%. Zoetis’s dividend payout ratio is presently 20.83%.
Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.
Further Reading: Average Daily Trade Volume – What You Need to Know
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.